<DOC>
	<DOC>NCT00661778</DOC>
	<brief_summary>This study assessed the efficacy and safety of Avastin in combination with docetaxel and cisplatin as first-line treatment of patients with metastatic or locally advanced non-small cell lung cancer. Patients received Avastin 15 mg/kg intravenously (IV), docetaxel 75 mg/m^2, and cisplatin 75 mg/m^2 on Day 1 of each 3-week cycle for a maximum of 6 cycles.</brief_summary>
	<brief_title>A Study of Avastin (Bevacizumab) in Combination With Docetaxel and Cisplatin in Patients With Metastatic or Locally Advanced Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Adult patients, â‰¥ 18 years of age. Stage IIIb or IV nonsmall cell lung cancer. Chemotherapynaive. Previous treatment for nonsmall cell lung cancer. Previous malignant tumor within last 5 years, except for basal cell skin cancer or preinvasive cervical cancer. Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to start of study. Recent or current chronic treatment with aspirin (&gt; 325 mg/day).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>